Exploring Praxis Precision Medicines’ elsunersen for Early-Onset SCN2A Developmental and Epileptic Encephalopathies

Executed on:Apr 14, 2026 7:45 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Mayo Clinic

Director of Pediatric Epilepsy at the Mayo Clinic & Co-founder of the Pediatric Epilepsy Research Consortium.
Clinical focus includes Early-onset epilepsies and epileptic encephalopathies, including West syndrome, Dravet syndrome, myoclonic atonic epilepsy of Doose, Lennox-Gastaut syndrome and CSW, Medically intractable pediatric epilepsy, Ketogenic diet therapy, and Surgical therapy for epilepsy.
Currently manages 10 adults with focal epilepsy and follows ~750 pediatric patients with Refractory Epilepsy.

Interview Goal

On this call, we aim to assess the clinical relevance and potential adoption of elsunersen based on EMBRAVE study findings, including its impact on seizure reduction, unmet need in SCN2A-DEE, differentiation from current treatments, and implications for future regulatory and commercial success.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.